Classic swine fever virus erns glycoprotein recombinant production for DIVA-compatible test systems

УДК 619:616.98.578:636.4:575.113:616-085.37
DOI 10.33861/2071-8020-2024-6-21-23

Akhunova A. R., Nasyrov Sh. M., Aleeva Z. Z., Arutyunyan G. S., Galeeva A. G., Efimova M. A.

Summary. Classical swine fever (hereinafter referred to as CSF) is a highly contagious disease of pigs and wild boars, leading to significant economic losses. According to the classification of the Office International des Epizooties, CFS is included in the list of quarantine diseases subject to mandatory registration and notification. Currently, the most effective option for the control and eradication of CSF in endemic countries is the development of marker vaccines with accompanying diagnostic tests corresponding to the DIVA (Differentiating Infected from Vaccinated Animals) strategy. The detection of antibodies to Erns is a reliable diagnostic approach for differentiating infected animals from vaccinated ones (DIVA) using labeled vaccines that induce a protective immune response to major glycoprotein E2 and at the same time show the absence of specific antibodies to the Erns glycoprotein. In the course of this study, we have constructed a prokaryotic expression system for the Erns glycoprotein fragment. Despite the fact that more than 80% of the protein was expressed in the form of inclusion bodies, the described optimized methodological approach made it possible to achieve the yield of a soluble form of Erns in the amount of 20-22 mg per 1 liter of bacterial culture. It was found that purified Erns reliably binds to specific antibodies and makes it possible to differentiate infected from vaccinated animals. This fact demonstrates the possibility of using the proposed recombinant glycoprotein as the basis for a component of differential diagnosis for a labeled genetically engineered vaccine against CFS.

Keywords: classical swine fever, DIVA strategy, marked vaccines, recombinant vaccines, glycoprotein Erns, prokaryotic expression system.

Author affiliation:

Nasyrov Shamil M., Ph. D. in Veterinary Medicine, Leading Scientific Researcher of the Laboratory of Viral Anthropozoonoses of the Federal Center for Toxicological, Radiation, and Biological Safety; Nauchnyy gorodok-2, Kazan, 420075; e-mail: shamyl777@mail.ru;

Аleeva Zamilya Z., Junior Scientific Researcher of the Laboratory of Viral Anthropozoonoses of the Federal Center for Toxicological, Radiation, and Biological Safety; Nauchnyy gorodok-2, Kazan, 420075.

Arutyunyan Guzaliya S., Junior Scientific Researcher of the Laboratory of Viral Anthropozoonoses of the Federal Center for Toxicological, Radiation, and Biological Safety; Nauchnyy gorodok-2, Kazan, 420075.

Galeeva Antonina G., Ph. D. in Veterinary Medicine, Leading Scientific Researcher, Head of the Laboratory of Viral Anthropozoonoses of the Federal Center for Toxicological, Radiation, and Biological safety, Senior Scientific Researcher of the Interdepartmental Laboratory of Biotechnology and Immunology of the Kazan State Academy of Veterinary Medicine named after N. E. Bauman; Nauchnyy gorodok-2, Kazan, 420075; e-mail: antonina-95@yandex.ru.

Efimova Marina A., D. Sc. in Biology, Leading Scientific Researcher of the Laboratory of Viral Anthropozoonoses of the Federal Center for Toxicological, Radiation, and Biological Safety, Professor of the Department of Epizootology and Parasitology of the Kazan State Academy of Veterinary Medicine named after N. E. Bauman; Nauchnyy gorodok-2, Kazan, 420075; e-mail: marina-2004r@mail.ru.

Responsible for correspondence with the editorial board: Akhunova Alsu R., graduate student, junior scientific researcher of the Laboratory of Viral Anthropozoonoses of the Federal Center for Toxicological, Radiation, and Biological Safety; Nauchnyy gorodok-2, Kazan, 420075; phone: 8-927-4681865; e-mail: aahunova@inbox.ru.